<p>随着美国股市在美联储决定降息后出现上涨，投资者密切关注内部持股比例高的成长型公司。在这种环境下，像 Krystal Biotech 这样的股票，内部人士持有显著股份，尤其具有吸引力，因为它们通常在不断变化的经济条件下传达出对公司潜力的信心。</p>
<h3>美国内部持股比例高的十大成长型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>超微计算机 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.5%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Cloudflare (NET)</td>
<td>10.2%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>131.7%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.5%</td>
<td>27.3%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们快速增长的美国内部持股比例高的公司筛选器中的 203 只股票的完整列表。</p>
<p>让我们从我们的专业筛选器中发现一些宝藏。</p>
<h2>Krystal Biotech (KRYS)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Krystal Biotech, Inc. 是一家商业阶段的生物技术公司，专注于发现、开发、制造和商业化针对美国高未满足医疗需求疾病的基因药物，市值为 69.5 亿美元。</p>
<p><strong>运营：</strong> 该公司从其专注于基因药物的细分市场中产生了 3.7316 亿美元的收入，针对美国高未满足医疗需求的疾病。</p>
<p><strong>内部持股比例：</strong> 10.3%</p>
<p><strong>收益增长预测：</strong> 每年 28.3%。</p>
<p>Krystal Biotech 展示了显著的增长，收益从一年前的 2718 万美元增加到 2025 年第三季度的 7937 万美元。该公司正在推进其基因药物管线，涵盖多个领域，得到了 FDA 对其 KB801 眼药水疗法的技术平台认证的支持。尽管交易价格低于估计的公允价值，但 Krystal 的收入和收益预计将快于市场平均水平增长，尽管最近几个月内部持股的详细信息尚不可用。</p>
<ul>
<li>通过阅读我们的分析师估计报告，深入了解 Krystal Biotech 的表现。</li>
<li>我们精心准备的 Krystal Biotech 估值报告暗示其股价可能低于预期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 KRYS 收益和收入增长</p>
<h2>凯悦酒店 (H)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 凯悦酒店公司在美国及国际上运营，市值约为 146.9 亿美元。</p>
<p><strong>运营：</strong> 凯悦的收入主要来自其自有和租赁的细分市场，收入为 12.4 亿美元，其次是管理和特许经营收入为 11.9 亿美元，分销贡献为 9.74 亿美元。</p>
<p><strong>内部持股比例：</strong> 11.2%</p>
<p><strong>收益增长预测：</strong> 每年 57.5%。</p>
<p>凯悦酒店公司正处于增长阶段，预计收入将以每年 17.8% 的速度增长，超过美国市场平均水平。尽管最近有内部人士出售股票，但公司受益于强大的内部持股和战略扩张，如凯悦机场酒店。其财务状况包括 15 亿美元的循环信贷额度和最近发行的 3.9983 亿美元的债券，利率为 5.4%。尽管目前尚未盈利，但预计在未来三年内收益将显著增长。</p>
<ul>
<li>在这里深入了解凯悦酒店的具体情况，查看我们的详细增长预测报告。</li>
<li>我们的估值报告显示凯悦酒店可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/27434017-c144-4ad1-8d3f-aca9ae5c07f4/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/27434017-c144-4ad1-8d3f-aca9ae5c07f4/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 H 收益和收入增长</p>
<h2>On Holding (ONON)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> On Holding AG 在全球开发和分销运动产品，市值约为 162.5 亿美元。</p>
<p><strong>运营：</strong> 该公司主要从其运动鞋细分市场产生收入，金额为 28.8 亿瑞士法郎。</p>
<p><strong>内部持股比例：</strong> 26.3%</p>
<p><strong>收益增长预测：</strong> 每年 30.1%。</p>
<p>On Holding 正在经历强劲增长，预计收益将以每年 30.1% 的速度增长，超过美国市场。该公司最近报告了强劲的第三季度业绩，销售额从去年同期的 6.358 亿瑞士法郎上升至 7.944 亿瑞士法郎，净收入显著改善，从 3050 万瑞士法郎提高至 1.189 亿瑞士法郎。尽管过去三个月内部交易活动仍不明朗，但 On Holding 的战略财务举措包括未来证券发行的货架注册申请。</p>
<ul>
<li>点击探索我们在 On Holding 收益增长报告中的详细发现。</li>
<li>根据我们的估值报告，On Holding 的股价可能偏高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/30b460e6-f1a8-445d-9f78-310d4e375cd1/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/30b460e6-f1a8-445d-9f78-310d4e375cd1/chart/ownership-breakdown"/></p>
<p>截至 2025 年 12 月的 ONON 持股结构</p>
<h2>将想法转化为行动</h2>
<ul>
<li>在这里探索我们快速增长的美国内部持股比例高的公司筛选器中的 203 个名称。</li>
<li>对其他选择感到好奇？人工智能即将改变医疗保健。这 30 只股票正在从早期诊断到药物发现方面进行工作。最重要的是 - 它们的市值都在 100 亿美元以下 - 现在仍然有机会提前介入。</li>
</ul>
<p>这篇来自 Simply Wall St 的文章是一般性的。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买卖任何股票的推荐，也不考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具如公司和/或信托实体间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式引用，时间范围为 1-3 年。</p>
<p>用于国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

KRYS

昂跑

凯悦酒店

<p>投资者正关注内部持股比例高的成长型股票，因为在美联储降息后，美国股市上涨。值得注意的公司包括 Krystal Biotech、凯悦酒店和昂跑，这些公司都显示出显著的盈利增长和内部持股比例。Krystal Biotech 的市值为 69.5 亿美元，内部持股比例为 10.3%，预计年盈利增长 28.3%。凯悦酒店的内部持股比例为 11.2%，盈利增长预测为 57.5%。昂跑的内部持股比例为 26.3%，盈利增长预测为 30.1%</p>

<p>As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, investors are closely watching growth companies with high insider ownership. In this environment, stocks like Krystal Biotech and others where insiders have significant stakes can be particularly attractive, as they often signal confidence in the company's potential amidst evolving economic conditions.</p>
<div class="lb-trans"><p>随着美国股市在美联储决定降息后出现上涨，投资者密切关注内部持股比例高的成长型公司。在这种环境下，像 Krystal Biotech 这样的股票，内部人士持有显著股份，尤其具有吸引力，因为它们通常在不断变化的经济条件下传达出对公司潜力的信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美国内部持股比例高的十大成长型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Super Micro Computer (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.5%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Cloudflare (NET)</td>
<td>10.2%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>131.7%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.5%</td>
<td>27.3%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>超微计算机 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.5%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Cloudflare (NET)</td>
<td>10.2%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>131.7%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.5%</td>
<td>27.3%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 203 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们快速增长的美国内部持股比例高的公司筛选器中的 203 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>让我们从我们的专业筛选器中发现一些宝藏。</p>
</div><h2>Krystal Biotech (KRYS)</h2>
<div class="lb-trans"><h2>Krystal Biotech (KRYS)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for diseases with high unmet medical needs in the United States, with a market cap of $6.95 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Krystal Biotech, Inc. 是一家商业阶段的生物技术公司，专注于发现、开发、制造和商业化针对美国高未满足医疗需求疾病的基因药物，市值为 69.5 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of $373.16 million from its segment focused on genetic medicines addressing diseases with significant unmet medical needs in the United States.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司从其专注于基因药物的细分市场中产生了 3.7316 亿美元的收入，针对美国高未满足医疗需求的疾病。</p>
</div><p><strong>Insider Ownership:</strong> 10.3%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 10.3%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 28.3% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 28.3%。</p>
</div><p>Krystal Biotech has demonstrated significant growth, with earnings increasing to US$79.37 million in Q3 2025 from US$27.18 million a year ago. The company is advancing its genetic medicines pipeline across various fields, supported by the FDA's platform technology designation for its KB801 eye drop therapy. Despite trading below estimated fair value, Krystal's revenue and earnings are expected to grow faster than the market average, although insider ownership details over recent months are unavailable.</p>
<div class="lb-trans"><p>Krystal Biotech 展示了显著的增长，收益从一年前的 2718 万美元增加到 2025 年第三季度的 7937 万美元。该公司正在推进其基因药物管线，涵盖多个领域，得到了 FDA 对其 KB801 眼药水疗法的技术平台认证的支持。尽管交易价格低于估计的公允价值，但 Krystal 的收入和收益预计将快于市场平均水平增长，尽管最近几个月内部持股的详细信息尚不可用。</p>
</div><ul>
<li>Get an in-depth perspective on Krystal Biotech's performance by reading our analyst estimates report here.</li>
<li>Our expertly prepared valuation report Krystal Biotech implies its share price may be lower than expected.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的分析师估计报告，深入了解 Krystal Biotech 的表现。</li>
<li>我们精心准备的 Krystal Biotech 估值报告暗示其股价可能低于预期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth"/></p>
<p>KRYS Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 KRYS 收益和收入增长</p>
</div><h2>Hyatt Hotels (H)</h2>
<div class="lb-trans"><h2>凯悦酒店 (H)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Hyatt Hotels Corporation operates as a hospitality company both in the United States and internationally, with a market cap of approximately $14.69 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 凯悦酒店公司在美国及国际上运营，市值约为 146.9 亿美元。</p>
</div><p><strong>Operations:</strong> Hyatt's revenue primarily comes from its Owned and Leased segment at $1.24 billion, followed by Management and Franchising at $1.19 billion, and Distribution contributing $974 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 凯悦的收入主要来自其自有和租赁的细分市场，收入为 12.4 亿美元，其次是管理和特许经营收入为 11.9 亿美元，分销贡献为 9.74 亿美元。</p>
</div><p><strong>Insider Ownership:</strong> 11.2%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 11.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 57.5% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 57.5%。</p>
</div><p>Hyatt Hotels Corporation is poised for growth, with revenue expected to increase by 17.8% annually, surpassing the US market average. Despite recent insider selling, the company benefits from strong insider ownership and strategic expansions like Hyatt Place Cancun Airport. Its financial position includes a $1.5 billion revolving credit facility and a recent $399.83 million bond issuance at 5.4%. Although currently unprofitable, earnings are projected to grow significantly over the next three years.</p>
<div class="lb-trans"><p>凯悦酒店公司正处于增长阶段，预计收入将以每年 17.8% 的速度增长，超过美国市场平均水平。尽管最近有内部人士出售股票，但公司受益于强大的内部持股和战略扩张，如凯悦机场酒店。其财务状况包括 15 亿美元的循环信贷额度和最近发行的 3.9983 亿美元的债券，利率为 5.4%。尽管目前尚未盈利，但预计在未来三年内收益将显著增长。</p>
</div><ul>
<li>Dive into the specifics of Hyatt Hotels here with our thorough growth forecast report.</li>
<li>Our valuation report here indicates Hyatt Hotels may be overvalued.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解凯悦酒店的具体情况，查看我们的详细增长预测报告。</li>
<li>我们的估值报告显示凯悦酒店可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/27434017-c144-4ad1-8d3f-aca9ae5c07f4/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/27434017-c144-4ad1-8d3f-aca9ae5c07f4/chart/earnings-and-revenue-growth"/></p>
<p>H Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 H 收益和收入增长</p>
</div><h2>On Holding (ONON)</h2>
<div class="lb-trans"><h2>On Holding (ONON)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> On Holding AG develops and distributes sports products globally, with a market cap of approximately $16.25 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> On Holding AG 在全球开发和分销运动产品，市值约为 162.5 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its Athletic Footwear segment, which amounts to CHF 2.88 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要从其运动鞋细分市场产生收入，金额为 28.8 亿瑞士法郎。</p>
</div><p><strong>Insider Ownership:</strong> 26.3%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 26.3%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 30.1% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 30.1%。</p>
</div><p>On Holding is experiencing robust growth, with earnings expected to increase by 30.1% annually, outpacing the US market. The company recently reported strong Q3 results, with sales rising to CHF 794.4 million from CHF 635.8 million year-over-year and net income significantly improved at CHF 118.9 million compared to CHF 30.5 million previously. While insider trading activity remains unclear over the past three months, On Holding's strategic financial maneuvers include a shelf registration filing for future securities offerings.</p>
<div class="lb-trans"><p>On Holding 正在经历强劲增长，预计收益将以每年 30.1% 的速度增长，超过美国市场。该公司最近报告了强劲的第三季度业绩，销售额从去年同期的 6.358 亿瑞士法郎上升至 7.944 亿瑞士法郎，净收入显著改善，从 3050 万瑞士法郎提高至 1.189 亿瑞士法郎。尽管过去三个月内部交易活动仍不明朗，但 On Holding 的战略财务举措包括未来证券发行的货架注册申请。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in On Holding's earnings growth report.</li>
<li>According our valuation report, there's an indication that On Holding's share price might be on the expensive side.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在 On Holding 收益增长报告中的详细发现。</li>
<li>根据我们的估值报告，On Holding 的股价可能偏高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/30b460e6-f1a8-445d-9f78-310d4e375cd1/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/30b460e6-f1a8-445d-9f78-310d4e375cd1/chart/ownership-breakdown"/></p>
<p>ONON Ownership Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ONON 持股结构</p>
</div><h2>Turning Ideas Into Actions</h2>
<div class="lb-trans"><h2>将想法转化为行动</h2>
</div><ul>
<li>Explore the 203 names from our Fast Growing US Companies With High Insider Ownership screener here.</li>
<li>Curious About Other Options? AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里探索我们快速增长的美国内部持股比例高的公司筛选器中的 203 个名称。</li>
<li>对其他选择感到好奇？人工智能即将改变医疗保健。这 30 只股票正在从早期诊断到药物发现方面进行工作。最重要的是 - 它们的市值都在 100 亿美元以下 - 现在仍然有机会提前介入。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p>这篇来自 Simply Wall St 的文章是一般性的。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买卖任何股票的推荐，也不考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具如公司和/或信托实体间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式引用，时间范围为 1-3 年。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用于国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达，随时随地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

Krystal Biotech 和另外两只增长型股票是内部人士押注的对象